TG THERAPEUTICS, INC. Unamortized Debt Issuance Expense
TG THERAPEUTICS, INC. (TGTX) had Unamortized Debt Issuance Expense of $3.83 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2024-08-09
- 2024-06-30: Unamortized Debt Issuance Expense $3.83M.
- 2024-03-31: Unamortized Debt Issuance Expense $4.47M.
- 2023-12-31: Unamortized Debt Issuance Expense $5.11M.
- 2023-09-30: Unamortized Debt Issuance Expense $5.75M.
| Period end | Unamortized Debt Issuance Expense | Unamortized Debt Issuance Expense as first filed |
|---|---|---|
| 2024-06-30 | $3.83M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $4.47M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $5.11M 10-Q · filed 2024-08-09 | |
| 2023-09-30 | $5.75M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $6.39M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $7.03M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $5.53M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $5.53M 10-Q · filed 2023-11-06 | $5.99M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $6.46M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $6.92M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $7.38M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $386.00K 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $617.00K 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $848.00K 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $1.08M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $1.31M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $1.54M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $1.77M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $2.00M 10-K · filed 2021-03-01 | |
| 2019-09-30 | -$2.23M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$2.46M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | -$2.69M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |